INNO-H
inno-h is an online marketing, advertising, and consulting company.
INNO-H
Social Links:
Industry:
Advertising Digital Marketing Marketing
Address:
Doksansadong, Seoul-t'ukpyolsi, South Korea
Country:
South Korea
Website Url:
http://www.inno-h.com
Status:
Active
Contact:
02-6332-6400
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Apple Mobile Web Clips Icon Content Delivery Network GStatic Google Static Content PostalAddress Schema LocalBusiness Schema
Similar Organizations
COLON
COLON offers web content, marketing, advertising, and clean energy solutions.
DesignARDOR Creative
DesignARDOR Creative is an online marketing, web promotion and creative solution company.
Flying Concepts
Flying Concepts is an online marketing, advertising, and consulting company.
Marketing Weekly
Niche Marketing knowledge provider and consultants.
THE AGENCY
THE AGENCY is a digital marketing, advertising, and marketing company.
Official Site Inspections
http://www.inno-h.com
- Host name: unalocated.63.wixsite.com
- IP address: 185.230.63.107
- Location: Ashburn United States
- Latitude: 39.018
- Longitude: -77.539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20147
More informations about "inno-h"
HK inno.N
HK inno.N’s K-CAB® wins a landmark victory in the second-instance trial for its substance patent 2025.02.12; HK inno.N opens HK inno.N Square, Unveiling an Integrated R&D Hub …See details»
HK inno.N - Crunchbase Investor Profile & Investments
HK inno.N was acquired by Korea Kolmar Co. for $1.1B on Feb 21, 2018. Transaction Name . HK inno.N acquired by Korea Kolmar Co. Acquired by . …See details»
IN-B00008 - Drug Targets, Indications, Patents - Synapse - Patsnap
Mar 20, 2025 IN-B00008, Initially developed by HK inno.N Corp., Now, its global highest R&D status is Phase 3, Therapeutic Areas: Endocrinology and Metabolic Disease,Skin and …See details»
HK inno.N’s K-CAB chosen as outstanding technology …
Nov 7, 2023 HK inno.N's indigenously developed drug K-CAB (tegoprazan) has been recognized as an outstanding technology that has contributed to the development of the Korean industry. On Tuesday, HK inno.N announced that …See details»
Organization | Inno.N - Purdue University
Organization Overview. First Clinical Trial. 2020 NCT04297865. First Marketed Drug. None First NDA Approval. None Last Known Activity ... HK inno.N Corporation Active Ingredients. Drugs …See details»
Kwak Dal-won - CEO of HK inno.N - koreawho.com
Kwak Dal-won is the CEO and President of HK inno.N. After CJ Healthcare was acquired by Korea Kolmar, its name was changed to HK inno.N. HK inno.N aims to maximize corporate …See details»
HK inno.N
Korea’s first sales organization dedicated to anti-cancer drugs is launched With the launch of home-grown pharmaceutical products, inno.N opens a new chapter in the industry. ... HK …See details»
HK inno.N signs CMO contract to produce clinical trial …
Nov 2, 2022 SEOUL --HK inno.N, a bio-health company in South Korea, will carry out the consignment production of clinical trial drugs for stem cell-derived organoid treatments under development by Cell in Cells, a domestic bio …See details»
Organization: HK inno.N - Cbonds.com
HK inno.N. Information about the issuer. News and credit ratings. . Tables with accounting and financial reporting.See details»
IN-B00001 - Drug Targets, Indications, Patents - Synapse - Patsnap
IN-B00001, Initially developed by HK inno.N Corp., Now, its global highest R&D status is Phase 1, Therapeutic Areas: Neoplasms, Active Indication: Neoplasms, Active Org.: HK inno.N Corp.. ...See details»
HK Innoen 2025 Company Profile: Stock Performance …
Information on stock, financials, earnings, subsidiaries, investors, and executives for HK Innoen. Use the PitchBook Platform to explore the full profile.See details»
HK inno.N
Jan 16, 2024 Geun Seog Song, vice president of R&D in HK inno.N explained, “we noted the value of cell and gene therapy, a representative player of the advanced therapy medicinal …See details»
IN M00001 - AdisInsight - Springer
Feb 28, 2025 IN M00001 (also known as IN C001) is an incrementally modified drug (IMD), being developed by HK inno.N (formerly CJ HealthCare), for the treatment of IN M00001 Next …See details»
IN-B014 - Drug Targets, Indications, Patents - Synapse - Patsnap
IN-B014, Initially developed by HK inno.N Corp., Now, its global highest R&D status is Discovery, Therapeutic Areas: Neoplasms, Active Indication: Neoplasms, Active ...See details»
HK inno.N
The alliances with multinational pharmaceutical firms, including AstraZeneca, Takeda, Eisai, Daiichi Sankyo, have allowed inno.N to make innovative drugs more widely available to the …See details»
IN C019 - AdisInsight - Springer
IN C019 is a fixed dose combination of incrementally modified drugs, being developed by HK inno.N (formerly CJ HealthCare) for the treatment of ureamia (kidney IN C019 ... If your …See details»
Hangover drinks: What are the best choices and do they really …
Jul 6, 2022 The most popular hangover drink in the country is Condition by South Korean pharmaceutical company HK inno.N., which has a market share of over 40 percent. The …See details»
IN-C011 - Drug Targets, Indications, Patents - Synapse
IN-C011, Initially developed by HK inno.N Corp., Now, its global highest R&D status is Pending, Therapeutic Areas: Endocrinology and Metabolic Disease. ... Originator Organization. HK …See details»
HK inno.N
R&D. inno.N charts the course for a healthier tomorrow through innovation in research and development.See details»
IN-C001 - Drug Targets, Indications, Patents - Synapse
IN-C001, Initially developed by HK inno.N Corp., Now, its global highest R&D status is Phase 1, Therapeutic Areas: Digestive System Disorders,Mouth and Tooth …See details»